1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc.

ZIVOW
ZIVO Bioscience, Inc.US flagNASDAQ Capital Market
0.04
USD
-0.51
- -
164,234.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-42,778.38
- -
- -
-26,267.67
-8,498.85
-4,045.65
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-10
1
-6
-6
-10
-15
-12
-9
-9
-9
-8
-13
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-45,528.64
- -
- -
-28,127.25
-8,513.44
-4,059.73
Working Capital
-3
-10
-6
-5
-11
-4
-22
-8
-11
6
- -
-2
- -
-3
LT Debt
1
1
- -
5
3
12
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-4
-10
-6
-9
-14
-16
-22
-8
-11
6
- -
-2
-1
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-3.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
1
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
4
Payables & Accruals
1
1
1
ST Debt
1
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2,045.84%
4,074.42%
-76.66%
Free Cash Flow
14.66%
18.62%
-25.63%
Net Income, GAAP
-81.94%
7.24%
72.1%
Sales/Revenue/Turnover
- -
- -
468.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
John Bernard Payne
Full Time Employees
7
Sector
Healthcare
Industry
Biotechnology
Address
21 East Long Lake Road Bloomfield Hills MI United States of America 48304
IPO Date
Dec 15, 2003
CIK
0001101026
Website
zivobioscience.com
Similar Companies
China Regenerative Medicine International Limited (8158.HK)
Genmab A/S (GMAB.CO)
Ayala Pharmaceuticals, Inc. (ADXS)
EASY BIO,Inc. (353810.KQ)
Novakand Pharma AB (publ) (NOVKAN.ST)
Alterity Therapeutics Limited (PRNAF)
Business
ZIVO Bioscience, Inc. (OTCQB: ZIVO) develops and commercializes nutritional compounds and bioactive molecules derived from proprietary algal strains for applications in human and animal health; the Michigan-based biotechnology company, founded in 1983 and headquartered at 2125 Butterfield Drive, Suite 100, Troy, MI, licenses its intellectual property including algae cultures, extracts, derivatives, and production techniques to manufacturers of dietary supplements, nutraceuticals, food ingredients, animal feeds, and pharmaceuticals. Core products target human dietary supplements and nutraceuticals such as ZIVOLife vegan protein powder, a shelf-stable dried green algae biomass rich in essential amino acids, beta glucans, fiber, polyphenols, iron, potassium, and vitamins A, E, and B12 that supports digestive health, gut health, and immune function; animal health solutions including feed ingredients for dairy cows to promote immune response against bovine mastitis, poultry formulations to enhance productivity, digestive efficiency, and resistance to coccidiosis, avian influenza, and other viral diseases; and early-stage developments for canine joint health, human immune modulation, skin health, anti-aging algal biomass, and pharmaceutical uses. The company operates in the biotech and agtech sectors, serving global customers with a pre-revenue focus on non-GMO, antibiotic-free, sustainable proteins and immune-modulating biologics that complement vaccines by reducing immunization lag time, protecting during vulnerable periods, enhancing responses, and mitigating immunosuppression. Recent developments include a June 2025 collaboration with a leading global animal health company for fully funded studies on ZIVO's compounds in poultry against coccidiosis and viral diseases to support USDA regulatory approval and commercialization; a late 2024 partnership with Alimenta Algae in Peru to scale production of ZIVOLife and with ZWorldwide for exclusive North American distribution, committing to purchase initial 18-month supply following strong sales; ongoing licensing negotiations for coccidiosis treatments expected to advance to formal agreements in early 2025; and an uplisting to the OTCQB market to improve trading visibility.